186 related articles for article (PubMed ID: 32759495)
1. Increased FGF-23 levels are linked to ineffective erythropoiesis and impaired bone mineralization in myelodysplastic syndromes.
Weidner H; Baschant U; Lademann F; Ledesma Colunga MG; Balaian E; Hofbauer C; Misof BM; Roschger P; Blouin S; Richards WG; Platzbecker U; Hofbauer LC; Rauner M
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32759495
[TBL] [Abstract][Full Text] [Related]
2. Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.
Balderman SR; Li AJ; Hoffman CM; Frisch BJ; Goodman AN; LaMere MW; Georger MA; Evans AG; Liesveld JL; Becker MW; Calvi LM
Blood; 2016 Feb; 127(5):616-25. PubMed ID: 26637787
[TBL] [Abstract][Full Text] [Related]
3. NUP98-HOX translocations lead to myelodysplastic syndrome in mice and men.
Slape C; Lin YW; Hartung H; Zhang Z; Wolff L; Aplan PD
J Natl Cancer Inst Monogr; 2008; (39):64-8. PubMed ID: 18648006
[TBL] [Abstract][Full Text] [Related]
4. BOK promotes erythropoiesis in a mouse model of myelodysplastic syndrome.
Kang SH; Perales O; Michaud M; Katz SG
Ann Hematol; 2019 Sep; 98(9):2089-2096. PubMed ID: 31203423
[TBL] [Abstract][Full Text] [Related]
5. Depletion of cytotoxic T-cells does not protect NUP98-HOXD13 mice from myelodysplastic syndrome but reveals a modest tumor immunosurveillance effect.
Gough SM; Chung YJ; Aplan PD
PLoS One; 2012; 7(5):e36876. PubMed ID: 22606303
[TBL] [Abstract][Full Text] [Related]
6. Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS.
Mei Y; Zhao B; Basiorka AA; Yang J; Cao L; Zhang J; List A; Ji P
Leukemia; 2018 Apr; 32(4):1023-1033. PubMed ID: 29263441
[TBL] [Abstract][Full Text] [Related]
7. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
[TBL] [Abstract][Full Text] [Related]
8. Impaired Mitophagy of Nucleated Erythroid Cells Leads to Anemia in Patients with Myelodysplastic Syndromes.
Jiang H; Yang L; Guo L; Cui N; Zhang G; Liu C; Xing L; Shao Z; Wang H
Oxid Med Cell Longev; 2018; 2018():6328051. PubMed ID: 29967662
[TBL] [Abstract][Full Text] [Related]
9. FGF23 Neutralizing Antibody Partially Improves Bone Mineralization Defect of HMWFGF2 Isoforms in Transgenic Female Mice.
Xiao L; Homer-Bouthiette C; Hurley MM
J Bone Miner Res; 2018 Jul; 33(7):1347-1361. PubMed ID: 29502359
[TBL] [Abstract][Full Text] [Related]
10. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia.
Lin YW; Slape C; Zhang Z; Aplan PD
Blood; 2005 Jul; 106(1):287-95. PubMed ID: 15755899
[TBL] [Abstract][Full Text] [Related]
11. Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13-driven mouse model.
Xu H; Menendez S; Schlegelberger B; Bae N; Aplan PD; Göhring G; Deblasio TR; Nimer SD
Blood; 2012 Oct; 120(15):3089-97. PubMed ID: 22927245
[TBL] [Abstract][Full Text] [Related]
12. Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome.
Chung YJ; Robert C; Gough SM; Rassool FV; Aplan PD
Leuk Res; 2014 Jan; 38(1):95-102. PubMed ID: 23958061
[TBL] [Abstract][Full Text] [Related]
13. FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis.
Coe LM; Madathil SV; Casu C; Lanske B; Rivella S; Sitara D
J Biol Chem; 2014 Apr; 289(14):9795-810. PubMed ID: 24509850
[TBL] [Abstract][Full Text] [Related]
14. A NUP98-HOXD13 leukemic fusion gene leads to impaired class switch recombination and antibody production.
Puthiyaveetil AG; Heid B; Reilly CM; HogenEsch H; Caudell DL
Exp Hematol; 2012 Aug; 40(8):622-33. PubMed ID: 22613470
[TBL] [Abstract][Full Text] [Related]
15. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
16. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis.
Claessens YE; Bouscary D; Dupont JM; Picard F; Melle J; Gisselbrecht S; Lacombe C; Dreyfus F; Mayeux P; Fontenay-Roupie M
Blood; 2002 Mar; 99(5):1594-601. PubMed ID: 11861273
[TBL] [Abstract][Full Text] [Related]
17. APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.
Raimbault A; Pierre-Eugene C; Rouquette A; Deudon C; Willems L; Chapuis N; Mathis S; Kunz C; Fricke H; Kosmider O; Bardet V; Fontenay M;
Oncotarget; 2016 Mar; 7(12):14898-911. PubMed ID: 26910909
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro.
Wang H; Yoshiko Y; Yamamoto R; Minamizaki T; Kozai K; Tanne K; Aubin JE; Maeda N
J Bone Miner Res; 2008 Jun; 23(6):939-48. PubMed ID: 18282132
[TBL] [Abstract][Full Text] [Related]
19. Acidic fibroblast growth factor inhibits osteoblast differentiation in vitro: altered expression of collagenase, cell growth-related, and mineralization-associated genes.
Tang KT; Capparelli C; Stein JL; Stein GS; Lian JB; Huber AC; Braverman LE; DeVito WJ
J Cell Biochem; 1996 Apr; 61(1):152-66. PubMed ID: 8726364
[TBL] [Abstract][Full Text] [Related]
20. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.
Balaian E; Weidner H; Wobus M; Baschant U; Jacobi A; Mies A; Bornhäuser M; Guck J; Hofbauer LC; Rauner M; Platzbecker U
Ann Hematol; 2019 Sep; 98(9):2063-2072. PubMed ID: 31312928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
